Physician profile
Robert Dobrzynski
NPI 1598863599
$244,929.31
in general payments reported to CMS, 2019-2025
18 companies · $45K in 2025
The $45K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $19K · 2021: $29K · 2022: $48K · 2023: $44K · 2024: $25K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $35K · Travel and Lodging: $5,722 · Food and Beverage: $4,214 · Consulting Fee: $2,647 · Education: $62.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,436.19 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $35,045.00 |
| Travel and Lodging | $5,721.53 |
| Food and Beverage | $4,214.08 |
| Consulting Fee | $2,646.94 |
| Education | $62.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $121,375.48 | 2019-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $43,396.64 | 2022-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $23,645.03 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $22,956.21 | 2020-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $21,691.43 | 2022-2023 | |
| Abbott Laboratories | $7,135.11 | 2019-2022 | |
| Ascensia Diabetes Care US INC. | $3,540.36 | 2024 | |
| Xeris Pharmaceuticals, INC. | $690.00 | 2021 | |
| Abbvie INC. | $141.60 | 2025 | |
| Amgen INC. | $102.98 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $49.13 | 2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $44.60 | 2019-2024 | |
| Mannkind Corporation | $42.50 | 2025 | |
| Sequel Med Tech, LLC | $41.02 | 2025 | Twiist |
| Lilly USA, LLC | $27.21 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $18.91 | 2022 | |
| Ascendis Pharma Endocrinology INC | $18.65 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dobrzynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.